Hyderabad: Suven Life Sciences will present clinical data on its investigational drug candidates Masupirdine (SUVN-502) and Tenaclidine (SUVN-I6107) at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference, being held in Boston, US, from November 16 to 19, 2026.

The two scientific presentations will highlight the clinical progress of the company's candidates being developed for central nervous system (CNS) disorders, including Alzheimer's disease and cognitive disorders.

In a presentation titled "Masupirdine (SUVN-502), A Pure 5-HT6 Receptor Antagonist: Baseline Demographic and Clinical Characteristics of the Phase-3 Clinical Study Targeting Agitation in Patients with Dementia of Alzheimer's Type" (P033), Suven will present baseline demographic and clinical characteristics of patients enrolled in its global Phase 3 study of Masupirdine for agitation associated with Alzheimer's disease dementia.

The company will also present findings from the Phase 1 evaluation of Tenaclidine, a pure M1 positive allosteric modulator, in healthy subjects. The presentation, titled "Tenaclidine (SUVN-I6107), A Pure M1 Positive Allosteric Modulator: First-in-Human Evaluation of Safety, Tolerability and Pharmacokinetics in Healthy Subjects" (P066), will cover outcomes from single ascending dose (SAD) and multiple ascending dose (MAD) studies.

The Tenaclidine findings will include data on safety, tolerability and pharmacokinetics, along with the effects of food, age and gender on its pharmacokinetic profile.

Commenting on the presentations, Venkat Jasti, Chairman and Managing Director of Suven Life Sciences, said completion of enrolment in the global Phase 3 Masupirdine study marked an important milestone in the candidate's clinical development. He said the baseline characteristics were consistent with published studies and represented a quality Alzheimer's disease population with agitation, adding that no major safety concerns had been identified to date.

The company expects to report topline results from the Masupirdine Phase 3 study in the second quarter of 2027.

Jasti also said Suven was encouraged by the clinical findings for Tenaclidine and planned to advance the candidate to patient studies.

Suven Life Sciences is focused on discovering and developing medicines for unmet medical needs in CNS disorders. Its clinical-stage pipeline includes Masupirdine for agitation in Alzheimer's disease dementia, Samelisant for excessive daytime sleepiness in narcolepsy, Ropanicant for major depressive disorder, and Usmarapride and Tenaclidine for cognitive disorders.

The company has completed enrolment in the global Phase 3 study of Masupirdine. Its pipeline also includes seven research-stage projects across multiple indications.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .